Search results
Antigenic Characterization of Novel Human Norovirus GII.4 Variants San Francisco 2017 and Hong Kong...
Centers for Disease Control and Prevention· 6 hours agoNovel Human Norovirus GII.4 Variants
FOSUN FOR GOOD, CREATING IMPACT: Fosun International Issued its 2023 ESG Report and the Second...
WPRI Providence· 4 hours agoFosun International Limited (HKEX stock code: 00656, "Fosun International"), together with its subsidiaries ("Fosun" or the "Group"), today issued the Environmental, Social and Governance (ESG ...
Signaturefd LLC Has $399,000 Position in Genmab A/S (NASDAQ:GMAB)
ETF DAILY NEWS· 8 hours agoSignaturefd LLC lessened its stake in shares of Genmab A/S (NASDAQ:GMAB – Free Report) by 26.1% during the fourth quarter, according to its most recent filing with the Securities & Exchange ...
Is Pfizer Stock A Sell As Shares Hit An 11-Year Low Amid The Search For Its Next Big Break?
Investor's Business Daily· 2 days agoIn fact, Pfizer says its pipeline of cancer drugs could lead to a potential eight new blockbuster...
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
Investor's Business Daily· 1 day agoBut he cautioned that even as Big Pharma companies buy into the space, they will still have to...
Allspring Global Investments Holdings LLC Invests $546,000 in OmniAb, Inc. (NASDAQ:OABI)
ETF DAILY NEWS· 9 hours agoAllspring Global Investments Holdings LLC acquired a new position in OmniAb, Inc. (NASDAQ:OABI – Free Report) during the fourth quarter, according to its most recent filing with the Securities ...
Why ‘free-from’ foods could be doing you more harm than good
The Telegraph via Yahoo News· 8 hours agoWhether you seek it out or stumble across it, no supermarket is without one; the free-from foods...
Novel T-cell engager, CDH17 X CD3 cabotamig (ARB202) continues to explore dosing in patients with...
FOX 59 Indianapolis· 2 hours agoThe second DMC review recommends the continuation of dose escalation in the clinical trial as per...
Doing What’s Right
KGTV San Diego· 1 hour agoKeep track of the way people are spending your tax dollars and treating your community.
FDA Approves Second Gene Therapy for Hemophilia B
Medscape· 10 hours agoPfizer reported a list price of $3.5 million for its new gene therapy, Beqvez, for adults with this rare bleeding disorder.